American Cryostem (American Cryostem) Change In Working Capital : $0.76 Mil (TTM As of Jun. 2022)

View and export this data going back to 2010. Start your Free Trial

What is American Cryostem Change In Working Capital?

American Cryostem's change in working capital for the quarter that ended in Jun. 2022 was $0.07 Mil.

American Cryostem's change in working capital for the fiscal year that ended in Sep. 2021 was $0.76 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

American Cryostem Change In Working Capital Historical Data

The historical data trend for American Cryostem's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

American Cryostem Change In Working Capital Chart

American Cryostem Annual Data

Trend

Sep12

Sep13

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Change In Working Capital

Get a 7-Day Free Trial

0.18

0.55

0.27

-0.42

0.76

American Cryostem Quarterly Data
	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22
Change In Working Capital	Get a 7-Day Free Trial															0.04	0.69	-0.30	0.30	0.07

American Cryostem Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.76 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

American Cryostem Change In Working Capital Related Terms

Thank you for viewing the detailed overview of American Cryostem's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

American Cryostem (American Cryostem) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » American Cryostem Corp (OTCPK:CRYO) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Meridian Road, Suite 5, Eatontown, NJ, USA, 07724

Website

http://www.americancryostem.com

American Cryostem Corp is a biotechnology company which standardizes adipose tissue-derived technologies (Adult Stem Cells) for the fields of Regenerative and Personalized Medicine. The company acts as an innovator of adipose tissue and stem cell platform technologies. It provides the clinical grade, adipose tissue and adult stem cell collection, processing, and cryo-preservation technology, providing first-in-class cellular therapy products and services for patients, physicians and researchers based on the transformative science of Regenerative and Personalized Medicine.

Executives

John S Arnone	director, officer: Chairman	111 GREAT NECK RD, GREAT NECK NY 11021
Anthony Francis Dudzinski	director, officer: COO	188 EAST BERGEN PLACE, SUITE 204, RED BANK NJ 07701
Acs Global, Inc.	10 percent owner	188 E. BERGEN PLACE, SUITE 204, RED BANK NJ 07701
Christopher Joseph Neill	10 percent owner	188 EAST BERGEN PLACE, SUITE 204, RED BANK NJ 07701
Hector Medina	director, 10 percent owner, officer: President and Director	1206 STAGECOACH TRAIL LOOP, CHULA VISTA CA 91915